A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Ranolazine on Major Adverse Cardiovascular Events in Subjects With a History of Chronic Angina Who Undergo Percutaneous Coronary Intervention With Incomplete Revascularization.

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Ranolazine on Major Adverse Cardiovascular Events in Subjects With a History of Chronic Angina Who Undergo Percutaneous Coronary Intervention With Incomplete Revascularization.

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Jul 2016

At a glance

  • Drugs Ranolazine (Primary)
  • Indications Angina pectoris; Cardiovascular disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms RIVER-PCI
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 13 Oct 2015 Primary endpoint has not been met. (Time from randomization to first occurrence of ischemia-driven revascularization or ischemia-driven hospitalization without revascularization)
    • 13 Oct 2015 Results published online in the Lancet.
    • 19 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top